Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Arbutus Biopharma
(NASDAQ:ABUS)
Intraday
$2.80
0.07
[2.56%]
After-Hours
$2.80
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$2.80
0.07
[2.56%]
At close: Apr 18
$2.80
0
[0.00%]
After Hours: 6:52PM EDT
Get Report
Watch
Q1 2024 Earnings in 13 days from now on Thu May 2nd, before the market open
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Arbutus Biopharma Stock (NASDAQ:ABUS)
Arbutus Biopharma Stock (NASDAQ: ABUS)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, April 04, 2024
Arbutus Vs. Moderna Patent Dispute Over Covid-19 Vaccine Gets Response From Judge
Vandana Singh
-
Apr 4, 2024, 2:32PM
Moderna Shares Slip Over Covid Vaccine Patent Dispute, But Chart Signals Potential Rebound Ahead
Surbhi Jain
-
Apr 4, 2024, 9:34AM
JMP Securities Reiterates Market Outperform on Arbutus Biopharma, Maintains $4 Price Target
Benzinga Newsdesk
-
Apr 4, 2024, 8:49AM
Arbutus Biopharma Announces Claim Construction Ruling In Ongoing Patent Infringement Lawsuit Against Moderna
Benzinga Newsdesk
-
Apr 4, 2024, 8:42AM
Wednesday, April 03, 2024
Arbutus Stock Soars 20% As It Heads To Trial With Moderna In Covid Vaccine Patent Claim
Neil Dennis
-
Apr 3, 2024, 3:37PM
Arbutus Biopharma shares are trading higher amid circulation of documents from an Arbutus/Genevant vs Moderna patent infringement lawsuit.
Benzinga Newsdesk
-
Apr 3, 2024, 12:57PM
Watching Arbutus Biopharma; Traders Circulate Arbutus/Genevant Vs Moderna Patent Infringement Lawsuit Claim Construction Order Court Documents
Benzinga Newsdesk
-
Apr 3, 2024, 12:22PM
Friday, March 01, 2024
Chardan Capital Reiterates Buy on Arbutus Biopharma, Maintains $4 Price Target
Benzinga Newsdesk
-
Mar 1, 2024, 7:48AM
HC Wainwright & Co. Maintains Buy on Arbutus Biopharma, Lowers Price Target to $5
Benzinga Newsdesk
-
Mar 1, 2024, 7:22AM
Thursday, February 29, 2024
Arbutus Biopharma's 2023 End Cash And Investments Of $132M Is Expected To Provide Cash Runway Into Q1 2026
Benzinga Newsdesk
-
Feb 29, 2024, 7:40AM
Arbutus Biopharma Q4 EPS $(0.12), Inline, Sales $2.15M Miss $4.79M Estimate
Benzinga Newsdesk
-
Feb 29, 2024, 7:36AM
Earnings Scheduled For February 29, 2024
Benzinga Insights
-
Feb 29, 2024, 5:15AM
Thursday, February 08, 2024
Watching Arbutus Biopharma; Hearing Jefferies Issues Note On Arbutus Biopharma On LNP Markman Hearing Saying Judge Favors Company Over Moderna
Benzinga Newsdesk
-
Feb 8, 2024, 1:13PM
Thursday, November 09, 2023
Barinthus Bio Said Initial Data From The Combination Of Imdusiran And VTP-300 Show Meaningful Reductions Of HBsAg Levels That Were Maintained Well Below Baseline.
Charles Gross
-
Nov 9, 2023, 4:27PM
Tuesday, November 07, 2023
Arbutus Biopharma Q3 2023 EPS $(0.12) Misses $(0.11) Estimate, Sales $4.658M Misses $4.752M Estimate
Benzinga Newsdesk
-
Nov 7, 2023, 7:34AM
Arbutus Says Announces Workforce Reduction Of 24% Effective Nov. 6, 2023, Primarily Affecting Research Function
Benzinga Newsdesk
-
Nov 7, 2023, 7:32AM
Arbutus CEO William Collier To Retire At The End Of 2023; Michael J. McElhaugh To Serve As Interim CEO
Benzinga Newsdesk
-
Nov 7, 2023, 7:21AM
Arbutus CEO William Collier To Retire Dec. 31, 2023
Benzinga Newsdesk
-
Nov 7, 2023, 7:18AM
Earnings Scheduled For November 7, 2023
Benzinga Insights
-
Nov 7, 2023, 6:34AM
Thursday, October 05, 2023
Small Biotech Promosome Drops Lawsuit Against Pfizer, BioNTech in COVID-19 Vaccine Patent Dispute
Vandana Singh
-
Oct 5, 2023, 3:04PM
Tuesday, September 12, 2023
HC Wainwright & Co. Reiterates Buy on Arbutus Biopharma, Maintains $6 Price Target
Benzinga Newsdesk
-
Sep 12, 2023, 6:27AM
Monday, September 11, 2023
Arbutus Says Discontinuing All Coronavirus And Oral RNA Destabilizer Programs, Including AB-343 And AB-161; Expects Pipeline Changes To Extend Cash Runway Through Q3 2025
Benzinga Newsdesk
-
Sep 11, 2023, 4:17PM
Friday, August 04, 2023
HC Wainwright & Co. Reiterates Buy on Arbutus Biopharma, Maintains $6 Price Target
Benzinga Newsdesk
-
Aug 4, 2023, 6:24AM
Chardan Capital Reiterates Buy on Arbutus Biopharma, Maintains $6 Price Target
Benzinga Newsdesk
-
Aug 4, 2023, 4:56AM
Thursday, August 03, 2023
Arbutus Biopharma Had Cash, Cash Equivalents And Investments In Marketable Securities Of $163.5M, With Cash Runway Into Q1 2025; 2023 Net Cash Burn To Range From Between $90M-$95M
Benzinga Newsdesk
-
Aug 3, 2023, 7:36AM
Arbutus Biopharma Q2 EPS $(0.10) Beats $(0.12) Estimate, Sales $4.65M Miss $5.02M Estimate
Benzinga Newsdesk
-
Aug 3, 2023, 7:34AM
Earnings Scheduled For August 3, 2023
Benzinga Insights
-
Aug 3, 2023, 6:59AM
Tuesday, July 11, 2023
HC Wainwright & Co. Reiterates Buy on Arbutus Biopharma, Maintains $6 Price Target
Benzinga Newsdesk
-
Jul 11, 2023, 6:17AM
Thursday, July 06, 2023
JMP Securities Reiterates Market Outperform on Arbutus Biopharma, Maintains $6 Price Target
Benzinga Newsdesk
-
Jul 6, 2023, 7:44AM
Thursday, June 22, 2023
HC Wainwright & Co. Reiterates Buy on Arbutus Biopharma, Maintains $6 Price Target
Benzinga Newsdesk
-
Jun 22, 2023, 6:10AM
Chardan Capital Reiterates Buy on Arbutus Biopharma, Maintains $6 Price Target
Benzinga Newsdesk
-
Jun 22, 2023, 4:16AM
Wednesday, June 21, 2023
Arbutus Biopharma Has Dosed The First Patient In The Additional Treatment Arm Of The AB-729 Phase 2a Triple Combination Clinical Trial That Has Been Expanded To Include A Pd-1 Monoclonal Antibody, Opdivo (Nivolumab)
Benzinga Newsdesk
-
Jun 21, 2023, 7:33AM
Arbutus Presents Preliminary AB-729 and Pegylated Interferon Alfa-2a Combination Data at the EASL Congress 2023
Benzinga Newsdesk
-
Jun 21, 2023, 3:30AM
Friday, May 05, 2023
HC Wainwright & Co. Reiterates Buy on Arbutus Biopharma, Maintains $6 Price Target
Benzinga Newsdesk
-
May 5, 2023, 6:58AM
Thursday, May 04, 2023
Arbutus Biopharma Q1 Exceeds Consensus View; Cuts Cash Burn Guidance
Lekha Gupta
-
May 4, 2023, 3:33PM
Recap: Arbutus Biopharma Q1 Earnings
Benzinga Insights
-
May 4, 2023, 7:46AM
Arbutus Biopharma Q1 EPS $(0.10) Beats $(0.14) Estimate, Sales $6.69M Beat $6.03M Estimate
Benzinga Newsdesk
-
May 4, 2023, 7:36AM
Earnings Scheduled For May 4, 2023
Benzinga Insights
-
May 4, 2023, 6:34AM
Wednesday, May 03, 2023
Arbutus Biopharma's Earnings Outlook
Benzinga Insights
-
May 3, 2023, 1:01PM
Friday, April 28, 2023
HC Wainwright & Co. Reiterates Buy on Arbutus Biopharma, Maintains $6 Price Target
Benzinga Newsdesk
-
Apr 28, 2023, 12:44PM
Thursday, April 27, 2023
Arbutus Biopharma Provides AB-729 Clinical Data and AB-161 Preclinical Data as Oral Presentations at the Global Hepatitis Summit 2023
Benzinga Newsdesk
-
Apr 27, 2023, 3:53AM
Tuesday, April 25, 2023
Arbutus Biopharma shares are trading lower after the company reported the FDA issued a clinical hold on its IND Application for AB-101.
Benzinga Newsdesk
-
Apr 25, 2023, 12:04PM
Why Arbutus Biopharma Stock Is Plunging Today
Vandana Singh
-
Apr 25, 2023, 9:57AM
Arbutus Reports FDA Clinical Hold On IND Application For AB-101, An Oral PD-L1 Inhibitor
Benzinga Newsdesk
-
Apr 25, 2023, 7:32AM
Tuesday, April 18, 2023
Arbutus To Present AB-729, AB-161 Data At Global Hepatitis Summit 2023
Benzinga Newsdesk
-
Apr 18, 2023, 4:24PM
Wednesday, April 12, 2023
US Court Favors Moderna In COVID-19 Vaccine Patent Infringement Case With Arbutus Biopharma
Vandana Singh
-
Apr 12, 2023, 10:37AM
Wednesday, April 05, 2023
HC Wainwright & Co. Reiterates Buy on Arbutus Biopharma, Maintains $6 Price Target
Benzinga Newsdesk
-
Apr 5, 2023, 6:36AM
Tuesday, April 04, 2023
Pfizer Slapped With Additional Patent Infringement Lawsuit Over Its Famed COVID-19 Shots
Vandana Singh
-
Apr 4, 2023, 2:08PM
Arbutus Biopharma And Genevant Sciences Filed A Lawsuit Against Pfizer And BioNTech Seeking Damages For Infringement Of U.S. Patents Regarding The Manufacture And Sale Of Any COVID-19 mRNA-LNP Vaccines
Benzinga Newsdesk
-
Apr 4, 2023, 7:55AM
Wednesday, March 29, 2023
JMP Securities Reiterates Market Outperform on Arbutus Biopharma, Maintains $6 Price Target
Benzinga Newsdesk
-
Mar 29, 2023, 8:18AM
Show more